Core 2: Mouse and Human Molecular Imaging

项目摘要/摘要：小鼠和人类分子成像核心 小鼠和人类分子成像（MHMI）核心将在转化研究中发挥核心作用 范德比尔特-英格拉姆癌症中心 (VICC) SPORE 在胃肠道 (GI) 癌症方面的使命，提供 三个项目、未来试点和可行性研究以及开发的最先进的成像资源 研究。 MHMI 核心将利用现有的、机构支持的设备和基础设施来提供 全方位的小动物和人类功能、分子和解剖成像资源，包括 磁共振成像 (MRI)、计算机断层扫描 (CT)、数字 X 射线、光学、单光子发射 计算机断层扫描 (SPECT) 和正电子发射断层扫描 (PET)。该核心的独特之处在于，VICC GI SPORE 研究人员还将获得利用 范德比尔特分子探针中心 (CMP) 的能力，包括高通量、面向多样性 适合开发新型成像化合物的合成能力，以及世界一流的临床前和 CMP 放射化学设施的 cGMP 资源。 MHMI 有三个具体目标： 目标 1. 发展、 优化并提供结直肠癌（CRC）的定量替代分子成像生物标志物 支持临床前和临床研究；目标 2. 为定制的成像数据分析提供支持 特定于项目的应用程序，包括多种成像模式的共同注册和集成，以及 作为所有临床前和临床研究的一部分执行的质量控制指标；目标 3. 工作 具有组织病理学和细胞分析 (TPCA) 核心以及生物统计学和生物信息学 (BBC) 建立请求联网、样本追踪、去识别化提取策略的核心 与成像、生物样本和其他研究数据相关的数据。转化目标：分子成像 阐明个体肿瘤的细胞和分子基础的巨大希望。补充到 基因组方法、分子成像提供了肿瘤“表型”的定量、功能测量，并且， 当与其他基于组织的或更新的“液体”活检方法结合使用时，可以提供丰富的生物学信息 有关个体肿瘤的信息。 MHMI 核心将为 VICC GI SPORE 调查人员提供一种机制 以及通过使用以下方法推进 CRC 前沿转化研究所需的专家人员 小鼠和人类的非侵入性分子成像。

PROJECT SUMMARY/ABSTRACT: Mouse and Human Molecular Imaging Core The Mouse and Human Molecular Imaging (MHMI) Core will play a central role in the translational research mission of the Vanderbilt-Ingram Cancer Center (VICC) SPORE in Gastrointestinal (GI) Cancer, providing state-of-the-art imaging resources for three projects, future pilot and feasibility studies, and developmental research. The MHMI Core will leverage existing, institutionally-supported equipment and infrastructure to offer a full range of small animal and human functional, molecular, and anatomical imaging resources, including magnetic resonance imaging (MRI), computed tomography (CT), digital X-ray, optical, single photon emission computed tomography (SPECT), and positron emission tomography (PET). A unique feature of this core, VICC GI SPORE investigators will also have access to novel probe development resources that leverage the capabilities of the Vanderbilt Center for Molecular Probes (CMP), including high-throughput, diversity-oriented synthesis capabilities suitable for developing novel imaging compounds, as well as world-class preclinical and cGMP resources of the CMP radiochemistry facility. The MHMI has three Specific Aims: Aim 1. To develop, optimize, and provide quantitative surrogate molecular imaging biomarkers of colorectal cancer (CRC) for support of preclinical and clinical research; Aim 2. To provide support for imaging data analysis customized to project-specific applications, including co-registration and integration of multiple imaging modalities, along with quality control metrics to be performed as part of all preclinical and clinical research studies; Aim 3. To work with both the Tissue Pathology and Cellular Analysis (TPCA) Core and the Biostatistics and Bioinformatics (BBC) Core to establish strategies for networking of requests, specimen tracking, extraction of de-identified data relating to imaging, biospecimens, and other research data. Translational goal: Molecular imaging holds great promise to illuminate the cellular and molecular underpinnings of individual tumors. Complementary to genomic approaches, molecular imaging provides a quantitative, functional measure of tumor `phenotype', and, when coupled with other tissue-based or newer `liquid' biopsy approaches, can provide a wealth of biological information about individual tumors. The MHMI Core will provide VICC GI SPORE investigators a mechanism and the expert personnel required for advancing cutting-edge translational research in CRC through the use of non-invasive molecular imaging in mice and humans.